Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 7
Submit an article Journal homepage
59
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Letter to the editor submitted in response to ‘Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study’

Maddalena Napolitanoa Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, ItalyCorrespondence[email protected]
,
Luca Potestiob Section of Dermatology – Department of Clinical Medicine and Surgery, University of Naples, Federico II, Napoli, Italy
,
Francesca Di Vicob Section of Dermatology – Department of Clinical Medicine and Surgery, University of Naples, Federico II, Napoli, Italy
,
Gabriella Fabbrocinib Section of Dermatology – Department of Clinical Medicine and Surgery, University of Naples, Federico II, Napoli, Italy
&
Cataldo Patrunoc Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
Pages 3066-3067 | Received 23 May 2022, Accepted 09 Jun 2022, Published online: 20 Jun 2022

References

  • Rankin BD, Georgakopoulos JR, Sachdeva M, et al. Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study. J Dermatolog Treat. 2022;1–3.
  • Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–432.
  • Patruno C, Stingeni L, Fabbrocini G, et al. Dupilumab and COVID-19: what should we expect? Dermatol Ther. 2020;33(4):e13502.
  • Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443–456.
  • Sasson J, Donlan AN, Ma JZ, et al. Safety and efficacy of Dupilumab for the treatment of hospitalized patients with moderate to severe COVID 19: a phase IIa trial. medRxiv. 2022; 2022.03.30.22273194.
  • Kridin K, Schonmann Y, Solomon A, et al. Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study. Immunol Res. 2022;70(1):106–113.
  • Chiricozzi A, Talamonti M, De Simone C, et al. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry. Allergy. 2021;76(6):1813–1824.
  • Ungar B, Lavin L, Golant AK, et al. The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis. Ann Allergy Asthma Immunol. 2022;128(6):734–736.
  • Napolitano M, Patruno C, Ruggiero A, et al. Safety of dupilumab in atopic patients during COVID-19 outbreak. J Dermatolog Treat. 2022;33(1):600–601.
  • Potestio L, Napolitano M, Bennardo L, et al. Atopic dermatitis exacerbation after Covid-19 vaccination in Dupilumab-treated patients. J Eur Acad Dermatol Venereol. 2022;36(6):e409–e411.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.